The retinoblastoma pathway is often inactivated in human tumors resulting in deregulated E2F activity that can induce both proliferation and cell death. Although the role of E2F in apoptosis is well characterized, little is known regarding its putative participation in other cell death pathways. We show here that activation of E2F1 upregulates the expression of four autophagy genesmicrotubule-associated protein-1 light chain-3 (LC3), autophagy-related gene-1 (ATG1), ATG5 and damageregulated autophagy modulator (DRAM). E2F1-mediated induction of LC3, ATG1 and DRAM is direct and indeed, endogenous E2F1 can be found bound to regions encompassing the promoters of these genes. Regulation of ATG5 by E2F1 is indirect. Importantly, we demonstrate that E2F1 activation enhances autophagy and conversely, reducing endogenous E2F1 expression inhibits DNA damage-induced autophagy. These studies identify E2F1 as a transcriptional regulator of autophagy, and for the first time establish a role for E2F1 in DNA damageinduced autophagy.
E2Fs are transcription factors best known for their involvement in the timely regulation of gene expression required for cell cycle progression (DeGregori and Johnson, 2006) . The product of the retinoblastoma (RB) tumor suppressor gene, pRB, exerts growth suppression mainly via inhibitory interactions with E2Fs (DeGregori and Johnson, 2006) . The pivotal role of this RB/E2F relationship in normal cellular proliferation is highlighted by the common incidence in human cancer of mutations in the RB pathway that result in deregulated E2F activity (Sherr, 1996) .
In addition to being fundamental regulators of proliferation, E2Fs modulate diverse cellular functions, such as DNA repair, differentiation and development (Dimova and Dyson, 2005) . At least one member of the E2F family, namely E2F1, can also mediate apoptosis (programmed cell death type I) (Ginsberg, 2002) . Programmed cell death (PCD) is an evolutionarily conserved phenomenon that is a necessary and important feature of various cellular processes. Apoptosis is the most characterized type of PCD; however, in recent years, alternative PCD types have been given more attention. In particular, autophagic cell death (PCD type II) is now considered an important cell death pathway that is alternative or complementary to apoptosis (Edinger and Thompson, 2004; Gozuacik and Kimchi, 2007) .
Autophagy, a vesicular trafficking process that mediates the degradation of long-lived proteins, is stimulated rapidly in response to various stresses, such as nutrient or growth factor deprivation (Klionsky and Emr, 2000) . Upon autophagy induction, a two-layered membrane structure containing cytoplasm and organelles is formed, called an autophagosome. Ultimately, autophagosomes fuse with lysosomes leading to degradation of their content, which results in the liberation of amino acids and fatty acids that can be metabolized or recycled to promote cell survival (Baehrecke, 2005) . This autophagic machinery can be utilized also for cellular suicide, a caspase-independent form of PCD (Gozuacik and Kimchi, 2007) . Thus, autophagy has dichotomous roles in cell death and cell survival and may play either a tumor suppressive or oncogenic part in tumor development.
Autophagy is induced following genotoxic stress (Shimizu et al., 2004; Crighton et al., 2007) . Exposure of cells to genotoxic agents results commonly in either growth arrest or PCD. The latter is considered to prevent the propagation of mutations and represents a key mechanism for averting malignancy. E2F1 is a major player in the cellular responses to genotoxic stress, in particular, in DNA damage-induced apoptosis (Stevens and La Thangue, 2004) . Therefore, we hypothesized that E2F1 may play a role also in DNA damage-induced autophagy. Here, data are presented that indicate that E2F1 activates the transcription of autophagy genes and, more generally, has the capacity to regulate autophagy.
To identify novel features of E2F1-induced cell death, we performed a DNA microarray analysis using cells containing an inducible E2F1, ER-E2F1 (Vigo et al., 1999) . In addition to known E2F target genes, the MAP1LC3 (LC3; microtubule-associated protein-1 light chain-3) and ATG1 (autophagy-related gene-1, also named ULK1 in human) genes, which encode critical components of autophagy, were noted to exhibit elevated mRNA levels in response to E2F1 activation (data not shown). To validate these microarray data and to survey whether E2F1 regulates the expression of other autophagy genes, we investigated the expression of various autophagy genes before and after induction of E2F1. Activation of ER-E2F1 by 4-hydroxytamoxifen (OHT) treatment is associated with significant increases in the mRNA levels of three key regulators of autophagy, ATG1, ATG5 and LC3 (Figure 1a ). Similar treatment of parental U2OS cells that does not contain ER-E2F1 did not affect the mRNA levels of these genes (Supplementary Figure 1) . ATG1 is a kinase that regulates autophagy induction. ATG5 is part of a ubiquitin-like pathway necessary for formation of the autophagic vesicle, and LC3 is also involved in autophagic vesicle formation. An E2F1-mediated increase in protein levels of ATG5 and LC3 was also detected (Figure 1b) . Importantly, expression of the adenovirus oncoprotein E1A, which disrupts RB/E2F complexes, similarly upregulates the expression of ATG1, ATG5 and LC3. This finding suggests that endogenous E2Fs are capable of influencing the regulation of these autophagy genes (Figure 1c) .
Recent studies have identified a gene encoding a lysosomal protein, the DRAM (damage-regulated autophagy modulator) gene, as a critical effector of p53-induced autophagy (Crighton et al., 2006) . As E2F1, like p53, plays a role in the response to DNA damage, we tested next whether E2F1 affects expression of DRAM. Following activation of ER-E2F1 by the addition of OHT, DRAM mRNA levels are significantly higher (Figure 1d ). In contrast to the increases in ATG1, ATG5 and LC3 mRNA levels that are detectable only 8-16 h after E2F1 activation, DRAM mRNA upregulation occurs faster, evident 4 h after E2F1 activation (Figures 1a and d and data not shown). Notably, activation of ER-E2F1 in p53-deficient human non-small cell lung carcinoma cells was found similarly to result in elevated levels of DRAM mRNA ( Figure 1e ). Taken together, these data support the premise that DRAM transcription is activated by E2F1 in a p53-independent manner.
To determine whether E2F1 affects directly the transcription of autophagy genes, we evaluated the influence of cycloheximide, a protein synthesis inhibitor, on transcriptional induction by ER-E2F1. As the ER-E2F1 fusion protein is activated by OHT in the absence of protein synthesis, any mRNAs upregulated upon ER-E2F1 activation in the presence of cycloheximide represent genes that are direct transcriptional targets of E2F1. DRAM mRNA expression is induced upon ER-E2F1 activation in both the absence and the presence of cycloheximide, indicating that DRAM is a direct target of E2F1 ( Figure 2a ). In contrast, increase in ATG5 expression in response to ER-E2F1 activation is inhibited by cycloheximide, indicating that ATG5 is not a direct target of E2F1 (Figure 2b ). Expression of LC3 is elevated following ER-E2F1 activation in both the absence and the presence of cycloheximide (Figure 2b ). However, LC3 mRNA levels increase in response to cycloheximide addition alone (suggesting that LC3 mRNA levels are regulated by a short-lived repressor) and, therefore, it is not possible to determine whether LC3 is a direct target of E2F1 using this method. Inconclusive data were obtained regarding the effect of cycloheximide on ATG1 expression (data not shown).
To explore further the possibility that the DRAM, LC3 and ATG1 genes are direct transcriptional targets of E2F, we searched the genomic sequences 1000 bp upstream of these genes for consensus E2F-binding sites. This in silico analysis revealed two and six consensus E2F-binding sites in the LC3 and ATG1 upstream regions, respectively (Figure 2c ). No consensus E2F-binding sites were found in the human DRAM promoter; however, a putative E2F-binding site is present in the first exon of the human DRAM gene at position þ 73 to 81. To further test whether E2F1 regulates DRAM expression via transcriptional activation, a fragment spanning the À867/ þ 111 region of the human DRAM gene was cloned into a luciferase reporter plasmid. Co-transfection of an E2F1 expression plasmid with this reporter into U2OS cells resulted in a 12-fold E2F1-induced activation, indicating that this expressing ER-E2F1 were treated with OHT for the indicated times (in hours). Total RNA was extracted and RT-PCR performed using primers specific for the DRAM and GAPDH genes. DRAM, damage-regulated autophagy modulator; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LC3, microtubule-associated protein-1 light chain-3; OHT, 4-hydroxytamoxifen; RT-PCR, reversetranscription PCR. (Figure 2d ). An E2F1 mutant that does not bind to DNA, E2F1E132, did not activate this DRAM-luciferase reporter (Figure 2d) .
E2F1 regulates autophagy
To substantiate that endogenous E2Fs regulate expression of ATG1, LC3 and DRAM, we performed chromatin immunoprecipitation analyses using chromatin from proliferating U2OS cells and antibodies directed against E2F1 and E2F4. The promoter fragments amplified were ATG1, À414/À169; LC3, À314/ À20 and DRAM, À599/À255. We found that endogenous E2F1 and E2F4 are associated detectably with all these promoters (Figure 2e) . No binding of endogenous E2Fs was detected to an unrelated genomic fragment (Figure 2e ). On the basis of these data, we conclude that the autophagy genes DRAM, LC3 and ATG1 are novel direct transcriptional targets of E2F.
Having discovered the capacity of E2F1 to regulate autophagy genes at the transcriptional level, next we set out to check whether E2F1 influences autophagy at the cellular level. We exploited observations that vesicular accumulation of endogenous LC3 is a marker of the autophagic process (Kirisako et al., 1999) . Specifically, in most unstimulated cells, LC3 exists in the LC3I form, which exhibits a diffuse distribution across the cytoplasm. In contrast, when autophagy is induced, LC3I is lipidated to become the LC3II form, which integrates into the autophagosome membrane and displays a distinctly punctate distribution (Kabeya et al., 2000) . The expression pattern of LC3 was examined before and (e) ChIP analysis was performed using U2OS cells. Crosslinked chromatin was precipitated using antibodies specific to E2F1, E2F4 and HA. Then ATG1, LC3, DRAM and b-actin promoter fragments were amplified by PCR. Input DNA represents 0.5% of total chromatin. ChIP, chromatin immunoprecipitation; DRAM, damage-regulated autophagy modulator; LC3, microtubule-associated protein-1 light chain-3; OHT, 4-hydroxytamoxifen; RT-PCR, reverse-transcription PCR.
S Polager et al after OHT addition in cultured parental tumor cells and in derivatives containing the inducible ER-E2F1. In the absence of OHT, as expected, only occasional puncta were observed, representing a basal level of autophagy.
No increase in the number of puncta was observed when parental cells were treated with OHT (Figure 3a) . In contrast, following E2F1 activation by addition of OHT to cells containing ER-E2F1, a notable increase in the number of puncta was detected (Figure 3a) . This E2F1-dependent increase in the number of puncta is modest but reproducible and suggests that E2F1 does indeed regulate autophagy. The modest influence of E2F1 activation on autophagy in this model system implies that E2F1 alone is not sufficient for strong induction of autophagy. However, following ER-E2F1 activation, we could also detect conversion of LC3I into the rapidly migrating lipidated form LC3II (Figure 1b) , further demonstrating autophagy regulation by E2F1. Autophagy can be induced by DNA damage (Shimizu et al., 2004; Crighton et al., 2007) and E2F1 is known to be involved in the DNA-damage response (Stevens and La Thangue, 2004 ). Therefore, we tested whether endogenous E2F1 influences autophagy in response to DNA damage. U2OS cells were infected with retroviruses that encode either two distinct E2F1-specific short hairpin RNAs (shRNAs) or a nonspecific shRNA.
As expected, endogenous E2F1 protein levels are reduced upon infection with the E2F1-specific shRNAcontaining retroviruses (Figure 3c) . Also, as expected, treatment of cells with the DNA-damaging agent etoposide results in a marked induction in the appearance of autophagosomes. Importantly, this etoposideinduced increase in the number of autophagosomes is much smaller in cells expressing the E2F1-specific shRNAs than in cells expressing the nonspecific shRNA (Figures 3b and c) . Knockdown of E2F4 had no effect on etoposide-induced autophagy (data not shown). Taken together, these data indicate that E2F1, but not E2F4, plays a role in DNA damage-induced autophagy. The observed ability of E2F1-specific shRNA expression to reduce DNA damage-dependent induction of autophagy is consistent with our finding that ectopic expression of E2F1 enhances autophagy. Taken together, these data indicate that endogenous E2F1 plays a role in autophagy, specifically in DNA damageinduced autophagy.
The induction of autophagy in response to stress may determine cell fate and therefore, must be tightly regulated. Extensive study of the autophagic process has indeed identified a number of regulatory mechanisms, featuring mainly phosphorylation-and ubiquitination-like events (Gozuacik and Kimchi, 2007) . However, Lower panel: protein levels of E2F1 and tubulin were assessed by western blot analysis using an anti-E2F1 antibody (Santa Cruz, Santa Cruz, CA, USA; sc-251) and anti-tubulin antibody (T9026; Sigma, Rehovot, Israel). LC3, microtubule-associated protein-1 light chain-3; OHT, 4-hydroxytamoxifen; shRNA, short hairpin RNA.
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recently, it has become clear that autophagy is regulated not only at the post-translational level, but also at the level of transcription. p53 activation promotes autophagy (Feng et al., 2005) and depends on p53-induced activation of the DRAM gene (Crighton et al., 2006) . DRAM transcription is also upregulated by the p53 family member, p73 (Crighton et al., 2007) . In addition, c-Myc overexpression induces autophagy (Tsuneoka et al., 2003) , and ectopic expression of either c-Myc or E2F-1 leads to an increase in levels of the autophagy inducer smARF (Reef et al., 2006) . Furthermore, Macleod and co-workers identified BNIP3 as an E2F-regulated gene that affects hypoxia-induced autophagic cell death (Tracy et al., 2007) . Also, E2F1 has been shown to bind with the promoter of the autophagy gene Beclin1, although an effect of E2F1 on Beclin1 expression remains to be demonstrated (Weinmann et al., 2001) .
Our data provide further support for the premise that autophagy is regulated at the transcriptional level by demonstrating for the first time that E2F1 regulates the expression of four autophagy genes-LC3, ATG1, ATG5 and DRAM.
Both E2F1 and p53 upregulate directly DRAM gene expression (Figures 1 and 2 and Crighton et al. (2006) ).
Notably, co-regulation by E2F1 and p53 has been documented for several pro-apoptotic genes, including ApafI, PUMA, Noxa and SIVA (Ginsberg, 2002; Fortin et al., 2004; Hershko and Ginsberg, 2004) . Moreover, p53 and E2F1 cooperate to mediate apoptosis (Wu and Levine, 1994) , but it remains to be seen whether and how they cooperate in inducing autophagy.
Our data taken together with the well-established role of E2F1 in apoptosis suggest that E2F1 regulates both apoptosis and autophagy. Thus, it is conceivable that autophagy and apoptosis are co-regulated at the transcriptional level. Future studies must address in more detail the relationships between E2F1-induced autophagy and autophagic cell death and between E2F1-induced autophagy and E2F1-induced apoptosis.
